{"id":36168,"date":"2026-09-21T17:37:00","date_gmt":"2026-09-21T12:07:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36168"},"modified":"2026-09-21T11:01:09","modified_gmt":"2026-09-21T05:31:09","slug":"semaglutide-patent-cliff","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff","title":{"rendered":"The Semaglutide Patent Cliff: A New Challenge for Novo Nordisk and Eli Lilly"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6ab29e0277916\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6ab29e0277916\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#Why_Semaglutides_Patent_Expiry_Isnt_a_Single_Date\" >Why Semaglutide&#8217;s Patent Expiry Isn&#8217;t a Single Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#Country-by-Country_When_Does_Semaglutide_Actually_Go_Off-Patent\" >Country-by-Country: When Does Semaglutide Actually Go Off-Patent?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#India_China_Brazil_Canada_South_Africa_The_Early_Wave_2026\" >India, China, Brazil, Canada, South Africa: The Early Wave (2026)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#EU4_Germany_France_Italy_Spain_and_the_United_Kingdom_The_Middle_Wave_2031\" >EU4 (Germany, France, Italy, Spain) and the United Kingdom: The Middle Wave (~2031)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#Japan_Aligned_With_the_Later_Wave_2031\" >Japan: Aligned With the Later Wave (~2031)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#United_States_The_Final_and_Most_Valuable_Frontier_2032%E2%80%932033\" >United States: The Final and Most Valuable Frontier (2032\u20132033)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#Semaglutide_Market_Size_and_Revenue_Projections_for_Obesity_Treatment\" >Semaglutide Market Size and Revenue Projections for Obesity Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#The_Real-World_Impact_Eli_Lilly_vs_Novo_Nordisk\" >The Real-World Impact: Eli Lilly vs Novo Nordisk<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#Novo_Nordisks_Obesity_Drug_Franchise_Under_Siege_on_Three_Fronts\" >Novo Nordisk&#8217;s Obesity Drug Franchise: Under Siege on Three Fronts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#Eli_Lilly_The_Chief_Beneficiary\" >Eli Lilly: The Chief Beneficiary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#The_Generics_Are_Already_Mobilizing\" >The Generics Are Already Mobilizing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\/#What_This_Means_Going_Forward\" >What This Means Going Forward<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026 (India, China, Brazil, Canada, South Africa), mid wave ~2031 (UK, EU4, Japan), late wave 2032\u201333 (US).<\/em><\/li>\n\n\n\n<li><em>India and China are the biggest near-term battlegrounds, covering ~40% of the world population and a third of global obesity cases.<\/em><\/li>\n\n\n\n<li><em>The US remains Novo&#8217;s most valuable and most protected market, shielded by a patent thicket through 2033.<\/em><\/li>\n\n\n\n<li><em>Eli Lilly has overtaken Novo Nordisk as GLP-1 market leader, with tirzepatide protected until 2036.<\/em><\/li>\n\n\n\n<li><em>Generics are mobilizing fast, especially in India and China, setting up a major access expansion.<\/em><\/li>\n<\/ul>\n\n\n\n<p>For nearly a decade, semaglutide has been pharma&#8217;s biggest growth story, the molecule behind <strong>OZEMPIC, WEGOVY, and RYBELSUS<\/strong> that turned Novo Nordisk into a healthcare giant and redefined how the world treats diabetes and obesity. But every blockbuster drug eventually hits the same wall: patent expiry. In 2026, that wall arrived, and not all at once, but market by market, in a staggered global rollout that&#8217;s already rewriting the competitive map of the <a href=\"https:\/\/www.delveinsight.com\/blog\/weight-loss-obesity-market\">anti obesity drug market<\/a>.<\/p>\n\n\n\n<p>This isn&#8217;t a simple &#8220;patent cliff&#8221; story, either. Because semaglutide&#8217;s protection expires at wildly different times in different countries, 2026 in some, 2032 in others, the drug is entering a strange, drawn-out twilight period where it&#8217;s simultaneously a generic commodity in New Delhi and a protected, premium-priced blockbuster in New York. Here&#8217;s exactly how the timeline breaks down, what it means for semaglutide market size and revenue projections for obesity treatment, and how the rivalry of Eli Lilly vs Novo Nordisk is playing out as a result.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-semaglutide-s-patent-expiry-isn-t-a-single-date\"><span class=\"ez-toc-section\" id=\"Why_Semaglutides_Patent_Expiry_Isnt_a_Single_Date\"><\/span><strong>Why Semaglutide&#8217;s Patent Expiry Isn&#8217;t a Single Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Most people assume a drug patent has one clean expiration date. In reality, semaglutide is protected by a stack of patents: a core composition-of-matter (molecule) patent, plus secondary patents covering formulations, delivery devices (like the FlexTouch pen), dosing regimens, and manufacturing processes. Each of these can expire on a different date, and each country applies its own rules for extending protection beyond the standard 20-year term. That&#8217;s why the same drug can be legally &#8220;off-patent&#8221; in India in March 2026 while remaining protected in the United States until December 2032, a gap of more than six years for the exact same molecule.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-country-by-country-when-does-semaglutide-actually-go-off-patent\"><span class=\"ez-toc-section\" id=\"Country-by-Country_When_Does_Semaglutide_Actually_Go_Off-Patent\"><\/span><strong>Country-by-Country: When Does Semaglutide Actually Go Off-Patent?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Rather than a single global &#8220;loss of exclusivity&#8221; date, semaglutide&#8217;s patent expiry is playing out in three distinct waves, largely dictated by how aggressively each jurisdiction allows patent-term extensions beyond the standard 20-year baseline. Emerging markets with weaker or no extension mechanisms, India, China, Brazil, Canada, and South Africa, have already crossed the finish line in 2026. Regulated markets with formal extension systems, like the UK, EU4, and Japan, buy Novo Nordisk roughly five more years of protection, pushing their cliff to around 2031. And the United States, thanks to its own patent-term-extension provisions plus a dense layer of secondary patents on devices, dosing, and manufacturing, holds out the longest, into 2032 and potentially 2033. The map below breaks down exactly where each major market stands, and why the gap between the earliest and latest expiry dates stretches to more than six years for the same molecule.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-india-china-brazil-canada-south-africa-the-early-wave-2026\"><span class=\"ez-toc-section\" id=\"India_China_Brazil_Canada_South_Africa_The_Early_Wave_2026\"><\/span><strong>India, China, Brazil, Canada, South Africa: The Early Wave (2026)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The core global patent family for semaglutide stems from a PCT application filed in early 2006. In countries that apply the standard 20-year term without extension mechanisms, that clock ran out in March 2026. India never granted Novo Nordisk\u2019s semaglutide patent in the first place; it rejected it in 2019 on obviousness grounds. This meant Indian generic drugmakers could move almost immediately once the underlying IP landscape cleared, and within 24 hours of the broader patent expiry, generic launches were already underway. In China, the foundational patent (CN101133082B\/CN200680006674.6) expired on <strong>20 March 2026<\/strong>. Novo fought hard to maintain its patent protection, including securing a Supreme People\u2019s Court reversal that briefly upheld the patent\u2019s validity, but its request for a patent-term extension was rejected by China\u2019s CNIPA in September 2025. More than a dozen Chinese drugmakers have since filed for approval, although regulatory review, rather than patent law, has now become the key bottleneck delaying generic launches. In Canada, Novo\u2019s patent was allowed to lapse entirely, with no legal pathway available to reinstate it, while patents in Brazil and South Africa expired alongside India\u2019s in <strong>March 2026<\/strong>.<\/p>\n\n\n\n<p>Together, these early-wave markets represent roughly <strong>40% <\/strong>of the world&#8217;s population and an estimated <strong>33%<\/strong> of the global population of adults <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-causes-diagnosis-risk-factors-treatment-market\">living with obesity<\/a>, meaning the commercial stakes of this first wave are enormous, even if per-patient revenue is far lower than in the US or Western Europe.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"380\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Semaglutide-Core-Patent-Expiry-Timeline-by-Country-1024x380.webp\" alt=\"Semaglutide-Core-Patent-Expiry-Timeline-by-Country\" class=\"wp-image-36172\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Semaglutide-Core-Patent-Expiry-Timeline-by-Country-1024x380.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Semaglutide-Core-Patent-Expiry-Timeline-by-Country-300x111.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Semaglutide-Core-Patent-Expiry-Timeline-by-Country-150x56.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Semaglutide-Core-Patent-Expiry-Timeline-by-Country-768x285.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Semaglutide-Core-Patent-Expiry-Timeline-by-Country-1536x570.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Semaglutide-Core-Patent-Expiry-Timeline-by-Country.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eu4-germany-france-italy-spain-and-the-united-kingdom-the-middle-wave-2031\"><span class=\"ez-toc-section\" id=\"EU4_Germany_France_Italy_Spain_and_the_United_Kingdom_The_Middle_Wave_2031\"><\/span><strong>EU4 (Germany, France, Italy, Spain) and the United Kingdom: The Middle Wave (~2031)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Europe doesn&#8217;t use the same blunt 20-year cutoff. Instead, innovators can apply for Supplementary Protection Certificates (SPCs), an EU-wide (and UK-mirrored) mechanism that extends protection by up to five years to compensate for the time a drug spends in clinical trials and regulatory review before reaching the market.<\/p>\n\n\n\n<p>For semaglutide, this pushes core compound protection out to roughly <strong>March 2031 <\/strong>across most EU4 markets and the UK, with countries like Germany and Denmark potentially stretching slightly later, into <strong>early 2033<\/strong>, depending on national SPC filings and any pediatric-extension bonuses. Sandoz has already filed a biosimilar application with the European Medicines Agency, using a reformulated buffer and preservative system designed to sidestep secondary formulation patents, a sign that generic competitors are positioning years ahead of the actual cliff.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-japan-aligned-with-the-later-wave-2031\"><span class=\"ez-toc-section\" id=\"Japan_Aligned_With_the_Later_Wave_2031\"><\/span><strong>Japan: Aligned With the Later Wave (~2031)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Japan operates its own patent-term-extension system, similar in spirit to the US and EU mechanisms. Analysts expect Japanese protection to hold until <strong>approximately 2031<\/strong>, keeping it in step with Europe rather than the earlier-expiring emerging markets, though Japan&#8217;s biosimilar approval pathway is also expected to move more cautiously once patents do lapse.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-united-states-the-final-and-most-valuable-frontier-2032-2033\"><span class=\"ez-toc-section\" id=\"United_States_The_Final_and_Most_Valuable_Frontier_2032%E2%80%932033\"><\/span><strong>United States: The Final and Most Valuable Frontier (2032\u20132033)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The US is where Novo Nordisk&#8217;s real financial exposure sits, and it&#8217;s protected the longest. The core compound patent (US 10,525,129) is set to expire on <strong>5 December 2032<\/strong>, with a possible pediatric-exclusivity extension pushing it to <strong>mid-2033<\/strong>. Secondary patents cover everything from the FlexTouch injector pen (2029) to specific obesity dosing regimens (2031) to manufacturing processes (through 2033), a classic &#8220;patent thicket&#8221; strategy designed to make generic entry as difficult and drawn-out as possible even after the core molecule patent falls.<\/p>\n\n\n\n<p>Crucially, several Hatch-Waxman challenges from generic makers, including <strong>Mylan, Dr. Reddy&#8217;s, Apotex, and Sun Pharma<\/strong>, have already been settled confidentially, and at least 13 companies have formally notified the FDA of interest in eventually marketing generic semaglutide. Industry analysts widely peg 2032 as the realistic date when the US market opens up, though full generic saturation (especially for complex injectable formulations) will likely stretch into 2034\u20132035 given the FDA&#8217;s lengthy review timeline for peptide-based &#8220;complex generics.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-semaglutide-market-size-and-revenue-projections-for-obesity-treatment\"><span class=\"ez-toc-section\" id=\"Semaglutide_Market_Size_and_Revenue_Projections_for_Obesity_Treatment\"><\/span><strong>Semaglutide Market Size and Revenue Projections for Obesity Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Before diving into the competitive fallout, it&#8217;s worth sizing the prize. Combined semaglutide sales across OZEMPIC, WEGOVY, and RYBELSUS topped <strong>$35 billion<\/strong> in 2025 across the globe, with WEGOVY alone contributing roughly <strong>$12 billion<\/strong> and OZEMPIC around <strong>$19 billion<\/strong>, and the franchise had been compounding at close to <strong>40%<\/strong> annual growth in the years prior. That scale is exactly why the staggered patent expiry matters so much: even a partial erosion of pricing power in high-volume markets like India and China, layered on top of intensifying branded competition, is enough to swing Novo Nordisk&#8217;s full-year guidance from double-digit growth to a projected <strong>5\u201313%<\/strong> sales decline in 2026.<\/p>\n\n\n\n<p>Looking ahead, most industry forecasts still expect the global GLP-1 obesity-treatment market to keep expanding through the end of the decade, but the mix is shifting. Analysts increasingly project that growth will be driven less by semaglutide itself and more by (a) lower-cost generic and biosimilar semaglutide volume in early-wave markets, and (b) next-generation branded molecules, tirzepatide, oral GLP-1s, and emerging candidates like orforglipron and retatrutide, capturing a growing share of <a href=\"https:\/\/www.delveinsight.com\/blog\/obesity-drugs-by-revenue\">obesity drug revenue<\/a> in the still-protected US, EU, UK, and Japanese markets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-real-world-impact-eli-lilly-vs-novo-nordisk\"><span class=\"ez-toc-section\" id=\"The_Real-World_Impact_Eli_Lilly_vs_Novo_Nordisk\"><\/span><strong>The Real-World Impact: Eli Lilly vs Novo Nordisk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Patent expiry is only half the story. What makes 2026 such a pivotal year for semaglutide isn&#8217;t just generics arriving in emerging markets; it&#8217;s that patent pressure is colliding head-on with the fiercest branded competition Novo Nordisk has ever faced, from Eli Lilly&#8217;s rival GLP-1 drug tirzepatide. The <a href=\"https:\/\/www.delveinsight.com\/blog\/novo-vs-eli-lilly-in-anti-obesity-drug-market\">Eli Lilly vs Novo Nordisk rivalry<\/a> has become the defining storyline of the semaglutide obesity treatment competitive landscape in 2026.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novo-nordisk-s-obesity-drug-franchise-under-siege-on-three-fronts\"><span class=\"ez-toc-section\" id=\"Novo_Nordisks_Obesity_Drug_Franchise_Under_Siege_on_Three_Fronts\"><\/span><strong>Novo Nordisk&#8217;s Obesity Drug Franchise: Under Siege on Three Fronts<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Novo entered 2026 guiding for a <strong>5\u201313% decline<\/strong> in adjusted sales and operating profit, marking a stunning reversal after years of more than 40% growth in its GLP-1 franchise. Management highlighted three compounding headwinds weighing on its obesity business. First, a clinical setback emerged as <strong>CagriSema<\/strong>, Novo\u2019s next-generation obesity drug once positioned as a successor to semaglutide, underwhelmed in a head-to-head trial against Lilly\u2019s tirzepatide, delivering 23% weight loss compared with 25.5% for tirzepatide. Novo\u2019s shares fell more than 16% in a single session following the results, wiping out the stock\u2019s entire post-semaglutide-launch rally.&nbsp;<\/p>\n\n\n\n<p>Second, increasing pricing pressure in the US is weighing on profitability, with a government agreement to lower drug prices and the inclusion of certain products under the Medicare price-negotiation provisions of the Inflation Reduction Act compressing margins in Novo\u2019s most profitable market. For some patients, list prices are expected to fall from roughly <strong>$959 to $274<\/strong> per month by 2027. Finally, the expiry of international patents across China, India, Brazil, and Canada in 2026 is opening the door to lower-cost generic and biosimilar competition in markets that collectively account for roughly one-third of the global obesity burden, potentially undermining the international volume growth Novo had been counting on to fuel its next phase of expansion.<\/p>\n\n\n\n<p>The cumulative effect has been brutal for shareholders: Novo&#8217;s stock has fallen roughly 75% from its 2024 peak, slipping the company out of Europe&#8217;s top-10 most valuable firms. Despite the turbulence, Novo Nordisk&#8217;s obesity products, led by <a href=\"https:\/\/www.delveinsight.com\/blog\/wegovy-for-obesity-and-weight-loss\">Novo Nordisk\u2019s WEGOVY<\/a>, including its new oral formulation and higher-dose options, remain central to the company&#8217;s turnaround strategy, and management is banking on international rollout and pipeline diversification to stabilize the business.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"414\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-in-USD-Billion-1024x414.webp\" alt=\"Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-(in-USD-Billion)\" class=\"wp-image-36173\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-in-USD-Billion-1024x414.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-in-USD-Billion-300x121.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-in-USD-Billion-150x61.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-in-USD-Billion-768x311.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-in-USD-Billion-1536x622.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Novo-Nordisk-vs-Eli-Lilly-Global-Revenue-Comparison-across-Obesity-and-Diabetes-in-USD-Billion.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-eli-lilly-the-chief-beneficiary\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_The_Chief_Beneficiary\"><\/span><strong>Eli Lilly: The Chief Beneficiary<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>While Novo has stumbled, Eli Lilly has surged. <strong>Tirzepatide <\/strong>(sold as MOUNJARO for diabetes and ZEPBOUND for obesity) has posted superior clinical trial results and is now outselling OZEMPIC and WEGOVY in key markets.&nbsp;<\/p>\n\n\n\n<p><em>Sadaf Javed, Functional Head of Forecasting and Analytics at DelveInsight, said that we project Lilly&#8217;s revenue climbing toward <\/em><strong><em>$77\u201378 billion<\/em><\/strong><em> by FY2026, compared with Novo&#8217;s roughly <\/em><strong><em>$47\u201348 billion<\/em><\/strong><em>, a gap that didn&#8217;t exist just two years ago. Lilly became the first trillion-dollar-market-cap healthcare company in 2025\u20132026, a symbolic passing of the crown in the obesity-drug race.<\/em><\/p>\n\n\n\n<p>Crucially, Lilly&#8217;s own US patents on tirzepatide don&#8217;t begin expiring <strong>until 2036<\/strong>, giving it several extra years of exclusivity runway compared to Novo&#8217;s semaglutide, a meaningful strategic cushion as the two companies fight over the same shrinking window of patent-protected pricing power.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-generics-are-already-mobilizing\"><span class=\"ez-toc-section\" id=\"The_Generics_Are_Already_Mobilizing\"><\/span><strong>The Generics Are Already Mobilizing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The early wave of patent expiries has sparked a genuine gold rush among generic and biosimilar manufacturers, particularly in India and China, as companies race to capitalize on the growing semaglutide opportunity. In India, major pharmaceutical companies such as <strong>Dr. Reddy\u2019s, Biocon, Cipla, Sun Pharma, Lupin, and Aurobindo Pharma<\/strong> are advancing plans to launch injectable and oral semaglutide products for both domestic and export markets. Meanwhile, <strong>OneSource Specialty Pharma<\/strong> is investing<strong> $100 million<\/strong> to expand its peptide manufacturing capacity and expects its revenue to potentially quadruple over the next three years, driven largely by anticipated demand for semaglutide. In China, at least <strong>16\u201317 companies<\/strong> have advanced generic semaglutide candidates to Phase 3 trials or the premarket filing stage. However, as of mid-2026, regulatory review delays rather than patent restrictions have allowed Novo Nordisk to retain practical market exclusivity in the country, despite the technical expiry of its patent.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"459\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/The-Semaglutide-Patent-Cliff-Effect-1024x459.webp\" alt=\"The-Semaglutide-Patent-Cliff-Effect\" class=\"wp-image-36174\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/The-Semaglutide-Patent-Cliff-Effect-1024x459.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/The-Semaglutide-Patent-Cliff-Effect-300x135.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/The-Semaglutide-Patent-Cliff-Effect-150x67.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/The-Semaglutide-Patent-Cliff-Effect-768x344.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/The-Semaglutide-Patent-Cliff-Effect-1536x689.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/The-Semaglutide-Patent-Cliff-Effect.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-this-means-going-forward\"><span class=\"ez-toc-section\" id=\"What_This_Means_Going_Forward\"><\/span><strong>What This Means Going Forward<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The semaglutide patent story is really two stories happening on different timelines. In emerging markets, the patent cliff has already hit, and a wave of cheap generics is expected to dramatically improve access to <a href=\"https:\/\/www.delveinsight.com\/blog\/oral-glp1-in-obesity-treatment\">GLP-1 therapy<\/a> for diabetes and obesity patients who previously couldn&#8217;t afford it. In the US, UK, EU4, and Japan, branded exclusivity holds for several more years, meaning the real pricing battle in the world&#8217;s most lucrative markets will be fought not with generics, but between Novo Nordisk&#8217;s obesity drug lineup and Eli Lilly&#8217;s competing branded portfolio, plus a growing list of next-generation candidates (oral GLP-1s, orforglipron, retatrutide) racing to succeed both of them.<\/p>\n\n\n\n<p>For Novo Nordisk, the message from 2026 has been unmistakable: patent protection alone can&#8217;t shield a company from a faster, more effective competitor. For the generics industry, especially in India and China, this is shaping up to be one of the largest single opportunities in pharmaceutical history, and a preview of how future high-value biologics may lose exclusivity: unevenly, market by market, and increasingly on the industry&#8217;s own terms rather than the originator&#8217;s.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/weight-loss-weight-management-obesity-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png\" alt=\"Obesity Market Outlook\" class=\"wp-image-28507\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/27183101\/Obesity-Market-Outlook-and-Assessment.png 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary For nearly a decade, semaglutide has been pharma&#8217;s biggest growth story, the molecule behind OZEMPIC, WEGOVY, and RYBELSUS that turned Novo Nordisk into a healthcare giant and redefined how the world treats diabetes and obesity. But every blockbuster drug eventually hits the same wall: patent expiry. In 2026, that wall arrived, and not all [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36170,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22409,22481,1173,22291,17668,23112,21050],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-36168","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-glp-1-receptor","tag-novo-nordisk-vs-eli-lilly","tag-obesity","tag-ozempic","tag-semaglutide","tag-semaglutide-patent","tag-wegovy","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Semaglutide Patent Cliff: Who Wins, Who Loses?<\/title>\n<meta name=\"description\" content=\"Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026, mid wave ~2031 (UK, EU4, Japan), late wave 2032\u201333 (US).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Semaglutide Patent Cliff: Who Wins, Who Loses?\" \/>\n<meta property=\"og:description\" content=\"Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026, mid wave ~2031 (UK, EU4, Japan), late wave 2032\u201333 (US).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-21T12:07:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/semaglutide-patent-cliff.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Semaglutide Patent Cliff: Who Wins, Who Loses?","description":"Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026, mid wave ~2031 (UK, EU4, Japan), late wave 2032\u201333 (US).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff","og_locale":"en_US","og_type":"article","og_title":"Semaglutide Patent Cliff: Who Wins, Who Loses?","og_description":"Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026, mid wave ~2031 (UK, EU4, Japan), late wave 2032\u201333 (US).","og_url":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-09-21T12:07:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/semaglutide-patent-cliff.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"The Semaglutide Patent Cliff: A New Challenge for Novo Nordisk and Eli Lilly","datePublished":"2026-09-21T12:07:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff"},"wordCount":2175,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/semaglutide-patent-cliff.webp","keywords":["GLP-1 receptor","Novo Nordisk vs. Eli Lilly","obesity","OZEMPIC","Semaglutide","Semaglutide Patent","Wegovy"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff","url":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff","name":"Semaglutide Patent Cliff: Who Wins, Who Loses?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/semaglutide-patent-cliff.webp","datePublished":"2026-09-21T12:07:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026, mid wave ~2031 (UK, EU4, Japan), late wave 2032\u201333 (US).","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/semaglutide-patent-cliff#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/semaglutide-patent-cliff.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/semaglutide-patent-cliff.webp","width":466,"height":284,"caption":"semaglutide-patent-cliff"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/semaglutide-patent-cliff-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GLP-1 receptor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novo Nordisk vs. Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">obesity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">OZEMPIC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Semaglutide<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Semaglutide Patent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Wegovy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">GLP-1 receptor<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk vs. Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">obesity<\/span>","<span class=\"advgb-post-tax-term\">OZEMPIC<\/span>","<span class=\"advgb-post-tax-term\">Semaglutide<\/span>","<span class=\"advgb-post-tax-term\">Semaglutide Patent<\/span>","<span class=\"advgb-post-tax-term\">Wegovy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 22 hours ago","modified":"Updated 1 day ago"},"absolute_dates":{"created":"Posted on Sep 21, 2026","modified":"Updated on Sep 21, 2026"},"absolute_dates_time":{"created":"Posted on Sep 21, 2026 5:37 pm","modified":"Updated on Sep 21, 2026 11:01 am"},"featured_img_caption":"semaglutide-patent-cliff","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36168"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36168\/revisions"}],"predecessor-version":[{"id":36175,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36168\/revisions\/36175"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36170"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36168"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36168"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}